Log in

NASDAQ:XFORX4 Pharmaceuticals News Headlines

$8.81
-0.06 (-0.68 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.60
Now: $8.81
$9.00
50-Day Range
$8.17
MA: $9.24
$9.98
52-Week Range
$5.84
Now: $8.81
$18.75
Volume68,213 shs
Average Volume68,020 shs
Market Capitalization$142.19 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52

Headlines

X4 Pharmaceuticals (NASDAQ XFOR) News Headlines

Source:
DateHeadline
X4 Pharmaceuticals Inc (NASDAQ:XFOR) Expected to Post Earnings of -$0.70 Per ShareX4 Pharmaceuticals Inc (NASDAQ:XFOR) Expected to Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - May 22 at 4:24 PM
Arsanis Inc (XFOR) Moves to Buy: Rationale Behind the UpgradeArsanis Inc (XFOR) Moves to Buy: Rationale Behind the Upgrade
finance.yahoo.com - May 13 at 1:57 PM
X4 Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of StockholdersX4 Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
finance.yahoo.com - May 12 at 5:38 PM
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2020 Results - Earnings Call TranscriptX4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:41 PM
X4 Pharmaceuticals (NASDAQ:XFOR) Announces  Earnings ResultsX4 Pharmaceuticals (NASDAQ:XFOR) Announces Earnings Results
www.americanbankingnews.com - May 9 at 12:16 AM
HC Wainwright Trims X4 Pharmaceuticals (NASDAQ:XFOR) Target Price to $21.00HC Wainwright Trims X4 Pharmaceuticals (NASDAQ:XFOR) Target Price to $21.00
www.americanbankingnews.com - May 8 at 7:49 PM
B. Riley Lowers X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $15.00B. Riley Lowers X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $15.00
www.americanbankingnews.com - May 8 at 7:49 PM
X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Reaffirmed by OppenheimerX4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - May 7 at 8:09 PM
X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial ResultsX4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial Results
finance.yahoo.com - May 7 at 4:48 PM
Paula Ragan Sells 2,400 Shares of X4 Pharmaceuticals Inc (NASDAQ:XFOR) StockPaula Ragan Sells 2,400 Shares of X4 Pharmaceuticals Inc (NASDAQ:XFOR) Stock
www.americanbankingnews.com - May 5 at 7:23 PM
X4 Pharmaceuticals Inc (NASDAQ:XFOR) Receives Consensus Rating of "Buy" from BrokeragesX4 Pharmaceuticals Inc (NASDAQ:XFOR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 3 at 6:14 AM
X4 Pharmaceuticals (XFOR) Scheduled to Post Quarterly Earnings on ThursdayX4 Pharmaceuticals (XFOR) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - April 30 at 6:35 AM
Zacks: Analysts Anticipate X4 Pharmaceuticals Inc (NASDAQ:XFOR) to Post -$0.83 Earnings Per ShareZacks: Analysts Anticipate X4 Pharmaceuticals Inc (NASDAQ:XFOR) to Post -$0.83 Earnings Per Share
www.americanbankingnews.com - April 29 at 9:00 AM
X4 Pharmaceuticals to Announce First Quarter 2020 Financial Results and Provide Recent Business Highlights on May 7, 2020X4 Pharmaceuticals to Announce First Quarter 2020 Financial Results and Provide Recent Business Highlights on May 7, 2020
finance.yahoo.com - April 23 at 12:13 PM
X4 Pharmaceuticals Showcases Strategic Focus on WHIM Syndrome During 2020 Analyst Day WebinarX4 Pharmaceuticals Showcases Strategic Focus on WHIM Syndrome During 2020 Analyst Day Webinar
finance.yahoo.com - April 7 at 3:57 PM
X4 Pharmaceuticals Inc.X4 Pharmaceuticals Inc.
www.barrons.com - March 27 at 11:36 PM
X4 Pharmaceuticals to Host 2020 Analyst Day Webinar:
A Deep Dive into WHIM SyndromeX4 Pharmaceuticals to Host 2020 Analyst Day Webinar: A Deep Dive into WHIM Syndrome
finance.yahoo.com - March 25 at 12:59 PM
Maryland biotech CEO: Virus outbreak won't stop opening of Boston R&D hubMaryland biotech CEO: Virus outbreak won't stop opening of Boston R&D hub
finance.yahoo.com - March 20 at 9:00 AM
X4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial ResultsX4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
finance.yahoo.com - March 12 at 7:39 AM
X4 Pharmaceuticals (XFOR) Presents At Cowen Health Care Conference - SlideshowX4 Pharmaceuticals (XFOR) Presents At Cowen Health Care Conference - Slideshow
seekingalpha.com - March 5 at 10:33 AM
X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide Recent Business Highlights on March 12, 2020X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide Recent Business Highlights on March 12, 2020
finance.yahoo.com - February 27 at 12:24 PM
X4 Pharmaceuticals to Present at Two Upcoming Investor Conferences in MarchX4 Pharmaceuticals to Present at Two Upcoming Investor Conferences in March
finance.yahoo.com - February 25 at 8:59 AM
X4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate MavorixaforX4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate Mavorixafor
finance.yahoo.com - February 12 at 3:11 PM
Street Watch: Top Analysts Make Moves on 3 Buy-Rated StocksStreet Watch: Top Analysts Make Moves on 3 Buy-Rated Stocks
finance.yahoo.com - December 26 at 11:40 AM
Hedge Funds Staying Clear Of X4 Pharmaceuticals, Inc. (XFOR)Hedge Funds Staying Clear Of X4 Pharmaceuticals, Inc. (XFOR)
finance.yahoo.com - December 20 at 6:21 PM
X4 Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?X4 Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - December 16 at 1:30 PM
B. Riley sees 146% upside in X4 Pharma in premarket analyst actionB. Riley sees 146% upside in X4 Pharma in premarket analyst action
seekingalpha.com - December 5 at 12:28 PM
X4 Pharmaceuticals Enters Oversold TerritoryX4 Pharmaceuticals Enters Oversold Territory
finance.yahoo.com - December 3 at 1:06 PM
X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B WarrantsX4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants
finance.yahoo.com - November 26 at 11:37 AM
X4 Pharmaceuticals Announces Proposed Public OfferingX4 Pharmaceuticals Announces Proposed Public Offering
finance.yahoo.com - November 25 at 6:06 PM
X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM SyndromeX4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM Syndrome
finance.yahoo.com - November 12 at 12:00 PM
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call TranscriptX4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 7:30 AM
X4 Pharmaceuticals EPS misses by $0.15X4 Pharmaceuticals EPS misses by $0.15
seekingalpha.com - November 7 at 8:07 AM
X4 Pharmaceuticals, Inc. to Host Earnings CallX4 Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 8:07 AM
X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business HighlightsX4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights
finance.yahoo.com - November 7 at 8:07 AM
X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital NeutropeniaX4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia
finance.yahoo.com - November 5 at 12:42 PM
X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General CounselX4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel
finance.yahoo.com - November 4 at 9:30 AM
X4 Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Provide Recent Business Highlights on November 7, 2019X4 Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Provide Recent Business Highlights on November 7, 2019
finance.yahoo.com - October 25 at 12:27 PM
X4 Pharmaceuticals Reports Positive Data from...X4 Pharmaceuticals Reports Positive Data from...
www.benzinga.com - September 30 at 6:47 AM
X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma PatientsX4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients
finance.yahoo.com - September 30 at 6:47 AM
X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and DevelopmentX4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development
finance.yahoo.com - September 18 at 8:43 AM
X4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in Combination with Axitinib at European Society for Medical Oncology (ESMO) 2019 CongressX4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in Combination with Axitinib at European Society for Medical Oncology (ESMO) 2019 Congress
finance.yahoo.com - September 12 at 12:03 PM
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - August 18 at 8:38 AM
X4 Pharmaceuticals (XFOR) Presents At Canaccord Genuity Growth Conference - SlideshowX4 Pharmaceuticals (XFOR) Presents At Canaccord Genuity Growth Conference - Slideshow
seekingalpha.com - August 13 at 3:25 PM
X4 Pharmas mavorixafor an Orphan Drug in Europe for rare immunodeficiency disorder; shares up 2%X4 Pharma's mavorixafor an Orphan Drug in Europe for rare immunodeficiency disorder; shares up 2%
seekingalpha.com - July 30 at 3:23 PM
X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM SyndromeX4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome
finance.yahoo.com - July 30 at 9:07 AM
X4 Pharmaceuticals to Attend Two Upcoming Investor ConferencesX4 Pharmaceuticals to Attend Two Upcoming Investor Conferences
finance.yahoo.com - July 24 at 3:23 PM
X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM SyndromeX4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome
finance.yahoo.com - June 26 at 3:18 PM
X4 Pharma to fund no-cost genetic testing for rare immune deficiency disorder; shares up 3%X4 Pharma to fund no-cost genetic testing for rare immune deficiency disorder; shares up 3%
seekingalpha.com - June 12 at 3:06 PM
X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A WarrantsX4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants
finance.yahoo.com - May 22 at 8:37 AM
This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.